Popular Articles

Safe For Passengers With Lung Disease To Travel By Air
Oxygen levels while flying are substantially less than at ground level. Current guidelines for in-flight oxygen levels are sufficient to support the needs of passengers with non-obstructed lung disease. According to two articles published in the Wiley-Blackwell journal, Respirology, commercial air travel appears to be safe for patients with lung disease as the current policies for the in-flight oxygen levels and availability of supplemental oxygen can adequately accommodate passenger"s needs.
new payday loan lenders
NHS Confederation Responds To Public Accounts Committee Report On NHS Funding
Nigel Edwards, the director of policy at the NHS Confederation, said, "The surpluses generated by the NHS over the 2007-2008 financial year are a testament to sound financial planning and an awareness on the part of everyone in the service of the need to spend public money carefully.
News of the day
Maine Fights For Senators' Votes, Grassley Can't Satisfy Either Side
Senators home for the Fourth of July recess found activists on each side of the health care debate waiting for them.
Public Health

In A "David Against Goliath" Move, SKIN.NY(R), Takes On Boots For Misleading Public By Making False Claims About No.7 Protect & Perfect Products, UK

Cult skincare brand SKIN.NY(R) have issued legal proceedings against beauty giant, Boots the Chemist, for misleading the public. In a recent blaze of publicity, Boots the Chemist claimed that their much-lauded Boots No.7 Protect and Perfect was the first anti-wrinkle cream to be proven to be effective in clinical trials. This is untrue. In fact, SKIN.NY Radical Restructure Complex(R) containing QAL-100(R) was the first complex skin cream with proven clinical trials published in the BJD over 6 years earlier in October 2003. SKIN.NY(R) also gives faster, broader skincare results. SKIN.NY(R) achieves more in three months than Boots No.7 does in six - SKIN.NY(R) delivers an additional 10% in wrinkle reduction. In fact the "inactive" control cream used in the SKIN.NY(R) study was as effective in 3 months as the Boots Serum was in a year. This also makes SKIN.NY(R) more cost-effective - three month"s supply of SKIN.NY(R) costs GBP99.00 whereas six month"s of Boots No.7 is GBP197.50. The facts speak for themselves - the trials SKIN.NY 3 month"s double blind clinical trials with product used twice daily. Trial data published in the British Journal of Dermatology (BJD) February 2003. Boots No.7 6 month"s double-blind clinical trials, 6 month"s open trials, product used once daily. Trial data published in The British Journal of Dermatology (BJD) April 2009. What did they test for SKIN.NY fine lines (measured with objective method laser profilometery, and also with photographic assessment, clinical assessment and self evaluation), deep lines, pore size, pigmentation, bags under the eyes, skin colour, telangiectasia (small dilated blood vessels), visible dryness, scaling, elasticity, tactile roughness Boots No.7 fine lines/wrinkles, (only clinical assessment, no objective clinical measurement was used) dyspigmentation, overall clinical grade of photo-ageing, tactile roughness The results SKIN.NY Facial wrinkles at 3 months - P SKIN.NY


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):